Global guidelines generally recommend GLP-1 or GIP/GLP-1 injections for: BMI 30 kg/m , or BMI 27 kg/m with at least one weight-related condition , such as: Type 2 diabetes High blood pressure High cholesterol Sleep apnea Fatty liver disease Not suitable for: Pregnant or breastfeeding individuals Anyone with a history of pancreatitis Patients with certain endocrine or thyroid cancers Children/adolescents (unless specifically approved) In Singapore, eligibility is assessed by a licensed doctor based on BMI, metabolic health, and previous response to lifestyle interventions
Often combined with silybin or used alongside ursodeoxycholic acid
Yes, inflammation leads to weight gain
PubMed Central , pmc.ncbi.nlm.nih.gov/articles/PMC4606321/
Um, we have some observational data that suggests these options are not linked to blood clots and they can be used at any age, um, and even in patients with a higher risk of um blood clots